Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy

Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival

(2010) Hidenori Takahashi et al.   ANNALS OF SURGERY

Defining Venous Involvement in Borderline Resectable Pancreatic Cancer

(2010) Yun Shin Chun et al.   ANNALS OF SURGICAL ONCOLOGY

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

(2010) Sonja Gillen et al.   PLOS MEDICINE

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

Pancreatic cancer: Current and future treatment strategies

(2009) K. Pliarchopoulou et al.   CANCER TREATMENT REVIEWS

Surgical Results After Preoperative Chemoradiation Therapy for Patients With Pancreatic Cancer

(2009) Sohei Satoi et al.   PANCREAS

Effects of Neoadjuvant Combined Chemotherapy and Radiation Therapy on the CT Evaluation of Resectability and Staging in Patients with Pancreatic Head Cancer

(2009) Yeo-Eun Kim et al.   RADIOLOGY

Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma

(2008) Kimberly M. Brown et al.   AMERICAN JOURNAL OF SURGERY

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

(2008) Volker Heinemann et al.   BMC CANCER

Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy

(2008) H. Golcher et al.   EJSO